83 results about "Bleeding time" patented technology

Devices, systems and methods for stimulating (e.g., noninvasively) a subject's inflammatory reflex are provided to reduce bleed time. The method may include the step of non-invasively stimulating the inflammatory reflex (e.g., the vagus nerve, the splenic nerve, the hepatic nerve, the facial nerve, and the trigeminal nerve) of a subject, such as by mechanical stimulation, in a manner which significantly reduces bleed time in the subject. Devices for non-invasively stimulating the inflammatory reflex may include a movable tip or actuator that is controlled to mechanically stimulate the ear. The devices may be hand-held or wearable, and may stimulate the cymba conchae region of the subject's ear.

The invention relates to production equipment for performing steam explosion pretreatment on biomass, in particular to pretreatment equipment in biomass utilization industry and provides a numerical control continuous steam explosion machine which can finish a supersonic speed steam explosion process in 8.75milliseconds according to a principle of a sliding sealing cover. The air bleeding section area of the steam explosion machine, namely the section area of the sliding sealing cover is equal to the section area of a high-pressure cylinder body, and the section area is in a fixed proportion with a steam explosion treatment volume, so that the problem that air bleeding time is prolonged along with the increasing of the treatment volume in the conventional hot blow process is solved, the power density of steam explosion is improved by three magnitude orders, the curing degrees of materials which are treated in batches are consistent, and the foundation is laid for the consistency of an industrial biochemical treatment process. Meanwhile, the machine has the fully-automatic feeding and discharging function, so that continuous steam explosion production is realized.

The invention relates to a starch composite hemostatic dressing of mesoporous silica microspheres, which adopts a sol-gel method and uses a three-block copolymer pluronic as a template agent to synthesize mesoporous silica microspheres with a pore diameter of about 5 nm. It is compounded with starch to prepare a mesoporous silicon oxide microsphere/starch composite hemostatic dressing, and the hemostatic performance of the composite material is observed through animal experiments. The mesoporous silica microsphere/starch composite material not only has strong water absorption performance, but also has obvious in vitro coagulation performance, which can significantly shorten the partial thromboplastin time and prothrombin time. The mesoporous silica microsphere/starch composite material can prevent the bleeding of the rabbit's back skin and liver injury and shorten the bleeding time, and has obvious hemostatic effect.

The invention relates to dendrobe aqueous extract and application thereof, and belongs to the technical field of pharmacy. The dendrobe aqueous extract disclosed by the invention is obtained by the following method: a, cutting dendrobe into pieces by scissors and adding the dendrobe pieces to water in the proportion W/V of 1:(10-20) for boiling; continuously keeping the boiling state for 2 hours to 4 hours after the drendrobe is boiled in the water; removing the residues by filtering through gauze and collecting the water extract; b, repeating the step a for twice to four times, combining the extracting solution every time; and freezing and drying the extracting solutions to obtain powder dendrobe water extract. The dendrobe is wild or artificially-cultivated fresh dendrobe or dried dendrobe. The invention further relates to the application of the dendrobe aqueous extract in preparing hemostatics. According to the dendrobe aqueous extract and the application thereof disclosed by the invention, the dendrobe aqueous extract provided by the invention has strong pharmacological action, the bleeding time is remarkably shortened and the medical prospect of the dendrobe aqueous extract in developing and preparing hemostatics are disclosed; and secondly, a novel application field of the dendrobe is developed.

The invention discloses an eucheuma polypeptide extract, as well as a preparation method and application thereof. A polypeptide extract is prepared from an eucheuma raw material. Experiments prove that the extract has good new performances of resisting platelet aggregation, prolonging bleeding time and coagulation time and inhibiting thrombosis, and can be applied to preparation of medicines, medicinal components, prodrugs or health products for resisting platelet aggregation or thrombus.

The present invention relates to a method of establishing a rat bleeding cerebral infarction animal model by a collagenase inducement method, comprising the following steps: (1) the preparation of the rat, (2) preparing for a PE sleeve improved linear pin, (3) establishing a cerebral median occlusion model of a SD rat by a linear pin method which is making the model by inserting the linear pin into the artery outside the neck referred to Longa, Kuga etc., (4) pulling out a tube core and infusing the collagenase into the PE sleeve after the success of the cerebral median occlusion of the rat, (5) preparing for a reperfusion model and (6) putting a bleeding cerebral infarction rat model obtained by the steps back to a cage to breed continuously and processing for ethological grading towards the animal at different times after the operation respectively. The rat selected by the present invention is a grown male SD rat with low blood vessel aberrance rate, which improves the success rate of manufacturing the model. The bleeding quantity and the bleeding time of the established animal model can be controlled manually, and the operation wound is little, which does not influence the rat limb function and the ethological grading is exact, which has good stability and repeatability.

The invention includes an in vitro bleeding time device having an opening through a sheet of material across an outlet. At least a portion the sheet of material contains a coating which includes collagen type I, fibrinogen, fibronectin, and von Willebrand factor. The invention includes a blood coagulation analysis system which has a device with an internal chamber for receiving a blood sample through an inlet. A sheet of material spans a flowpath through a single device outlet. A controller regulates pressure and or flow rate within the device. The invention includes a method for analyzing blood coagulation. Blood provided into a device chamber flows out through an opening through a sheet of material which spans the device outlet. A controller is utilized to control pressure and/or flow rate within the device by controlling the flow rate into the device during formation of a clot blockage of the opening.

The invention discloses a Chinese herbal preparation for treating uterine bleeding after drug abortion, which is made from following raw materials in weight proportion: 2 to 6 parts of astragalus root, 1.5 to 4 parts of agrimony, 0.9 to 2 parts of Chinese angelica, 2 to 4 parts of leonurine, 0.3 to 0.9 part of powdered notoginseng root, 1.5 to 3 parts of portulaca, 1 to 3 parts of redroot gromwell root, 0.8 to 2 parts of aspidium, 0.6 to 2 parts of bitter orange and 0.6 to 2 parts of dried rehmannia root. The invention integrates the functions of Qi supporting and blood enriching, muscle regeneration and hemostasis and heat clearing and blood cooling and cures uterine bleeding after drug abortion with safety, reliability and without pain and can obviously increase complete abortion rate and reduce bleeding quantity of the uterine to shorten bleeding time and avoid twice curettage.

The invention belongs to the technical field of chitosan derivative preparation, and particularly provides a functionalized chitosan microsphere and a preparation method and application thereof. The method comprises the steps that high-molecular-weight chitosan is degraded to obtain a low-molecular-weight chitosan solution, then chitosan is subjected to functional modification through lactobionic acid and ammonium ferrous sulfate, and finally, under the action of sodium polyphosphate, cross-linking reaction is conducted to obtain the functional chitosan microsphere. The functional chitosan microsphere can be used for preparing hemostatic materials, the bleeding time is greatly shortened, the bleeding amount is reduced, and the hemostatic effect is good.

The invention relates to the field of medicine, which discloses the application of anti-angiohemophilia factor A3 zone bifunctional monoclonal antibody in preparation of antithrombotic medicine. The anti-angiohemophilia factor A3 zone bifunctional monoclonal antibody has the effect of obviously restraining periodic blood flow reduction (CFRs) in animal bodies, not only restrains the combination of blood plasma VWF and collagen, but also restrains human platelet aggregation induced by ristomycin. Moreover, the anti-angiohemophilia factor A3 zone bifunctional monoclonal antibody has high affinity with the VWF, can keep the pharmacodynamic effect of antithrombosis in a macaque body within a wider time window, does not delay platelet count and bleeding time in the macaque body, does not affect the blood coagulation function, and has no haemorrhage side effects as antithrombotic medicine, wherein the anti-angiohemophilia factor A3 zone bifunctional monoclonal antibody adopts monoclonal antibody secreted by hybridoma cell strain SZ-125 with the preservation number of CGMCC NO.2501.

The invention relates to a nasal cavity hemostat, a sinus cavity hemostat and a hemostasis operation method. The nasal cavity hemostat comprises a hemostasis airbag, an airway conduit, a nasal vestibule plug, a fixed buckle, an inflating pipe, an indication balloon and an inflation valve, and is characterized in that: one end of the airway conduit is sleeved on the nasal vestibule plug; the fixed buckle is arranged on the nasal vestibule plug; thicknesses of two lateral walls of the hemostasis airbag are not equal. The sinus cavity hemostat comprises a hemostasis airbag, an inflating pipe, an indication balloon and an inflation valve, wherein the hemostasis airbag is of an ovular flat structure matched with the space inside the sinus cavity. The nasal cavity hemostat and the sinus cavity hemostat have the advantages that: the shape of the hemostasis airbag is matched with that of an operated cavity, and can be well attached to the nasal cavity of a patient when used, and hemostasis can be realized by virtue of physical compression to the surface of nasal mucosa; the pressure is uniformly and adjustable, the plug discomfort can be reduced; the contact with a bleeding wound of the nasal cavity can be possibly reduced in inserting and withdrawing processes, and secondary wound can be avoided; the patient can breath through the nasal cavity due to the airway conduit; the operation is convenient, the bleeding time can be shortened, complication can be reduced, and pains of patients can be lightened.

The invention relates to a medicine composition, in particular to the medicine composition containing tirofian and active antithrombotic component. The active components are the tirofiban and aspirin. The medicine composition contains 1 to 50mg of the tirofiban and the aspirin with 20 to 800mg of effective dose. Compared with using the tirofiban or the aspirin separately, the blooding time of the invention is prolonged, so the occurrence rate of blooding and thrombus is reduced. In addition, the medicine composition solves a problem that the medicine is difficult to be taken orally for the part of high-risk ACS patients who can not take the medicine orally or have poor compliance. Therefore, the medicine composition is beneficial to improving the compliance of the patients and the safe use of the medicine, etc.

Disclosed are apparatuses and methods for reducing or limiting blood loss and reducing bleed time in a subject by combined vagus and trigeminal stimulation. The apparatuses and methods may activate (e.g., electrically) one or more branches of the trigeminal nerve and may concurrently (at overlapping or near-overlapping time) independently activate the vagus nerve. This activation may be invasive or non-invasive.

Disclosed are apparatuses and methods for reducing or limiting bleeding (e.g., blood loss and/or bleeding time) in an animal by trigeminal stimulation. The apparatuses and methods may activate one or more branches of the trigeminal nerve. This activation may be invasive or non-invasive.

The invention provides for spray compositions comprising co-polymers comprising a core, water-soluble polymer and a peptide and a delivery solvent. The present invention provides for spray hemostatic systems that allow for quick and even distribution of hemostatic nanoparticles or synthetic platelets that reducing bleeding and improve outcomes in trauma. The invention provides for spray compositions comprising a co-block polymer coupled to a water soluble polymer, and a polymer delivery solvent. The invention provides for spray compositions which comprise nanoparticles that halve bleeding time in a femoral artery injury model, which allow for even distribution of the nanoparticles at a wound site and allow application to areas that are difficult to contact with other methods of administration.

The invention discloses an oligopeptide containing an Hyp-Gly sequence and having antiplatelet and antithrombotic functions. The invention provides the oligopeptide containing the Hyp-Gly sequence orsalt forms thereof. The oligopeptide containing an OG sequence can be prepared through artificial synthesis as well as enzymolysis of fish skin. The molecular weight of the oligopeptide containing theOG sequence is smaller than 1,000 Da, the mass ratio of the oligopeptide to total enzyme-digested products is 65%-95%, and the oligopeptide has a specific inhibition effect on ADP-induced platelet aggregation, can inhibit thrombosis, does not affect the blood coagulation function, does not prolong the bleeding time and is very small in bleeding risk; and the oligopeptide has the characteristics of resistance to gastrointestinal tract digestive enzyme enzymolysis and easiness in absorption.

The invention provides a cutting device for a standard wound of fingertip skin of a primate. The cutting device for the standard wound of the fingertip skin of the primate aims at forming the cutting device on the basis of a primate animal bleeding time measuring model (wound cutting on fingertip skin), the cutting device can effectively, fixedly and accurately cut off the fingertip skin to form into a fingertip standard wound with relative fixed thickness, force and accuracy, accordingly accurate and effective testing data can be obtained and meanwhile an uncertain result and uncomfortable visual feelings caused by an unarmed operating behavior by directly cutting the fingertip through the surgical knife. According to the cutting device for the standard wound of the fingertip skin of the primate, a hollow pipe-shaped object with a suitable size is sleeved on a finger to fix the finger and flatly unfold the finger, a protruding position inside the pipe is used to fix a fingernail position (the front edge of a white line of the fingernail is served as the criterion for the length of the finger) of the finger, a cutter pressure device with a spring is arranged right above the protruding, the thickness of the exposed finger portion is relatively consistent when the finger is abutted,, then the upper cutter with the spring is pressed to cut off the fingertip skin, and the device is taken out conveniently, and the bleeding time is recorded.

The invention discloses a compound polysaccharide anti-hemorrhagic thin film and a preparation method thereof.The thin film is prepared from, by mass, 10-20 parts of chitosan, 2-8 parts of glucose, 3-6 parts of methylcellulose, 1-5 parts of gelatin, 4-7 parts of pectin, 4-7 parts of sodium trimetaphosphate, 8-20 parts of polyhydric alcohols, 5-8 parts of agar, 2-8 parts of sorbic acid, 5-10 parts of sodium alginate, 3-6 parts of panax notoginseng, 1-3 parts of sodium fumarate and 2-5 parts of sanguisorba officinalis.A polysaccharide serves as a matrix, proper anti-hemorrhagic components and auxiliaries are added, and the film-shaped anti-hemorrhagic material is prepared.Compared with conventional powder or spray, the film-shaped anti-hemorrhagic material can stop bleeding in two aspects synchronously.In the early time of bleeding, the film body is similar to tourniquet and can quickly stop bleeding, the anti-hemorrhagic components in the film synchronously stop bleeding at the same time, and the thin film has dual anti-hemorrhagic functions, greatly shortens bleeding time and is obvious in anti-hemorrhagic effect and convenient to use.

The invention provides an arterial hemostasisdressing and a preparation method. The arterial hemostasisdressing comprises a calcium alginate non-woven fabric layer, wherein a calcium alginate and chitosancomposite non-woven fabric layer is connected to one surface of the calcium alginate non-woven fabric layer. Compared with variousalginate and chitosan hemostasisproducts sold in the market, the arterial hemostasisdressing can obviously shorten the arterial bleeding time and reduce the bleeding amount, and can be used for arterial bleeding at four limbs and special parts including the thorax and abdomen, armpits, groin and the like; compression binding is not required for arterial bleedingof four limbs, and generalbinding can be performed with bandage; for the special parts, hemostasis can be realized when the dressing is applied to a bleeding part with a hand for 2-3 min, and avascular necrosis easily caused by long-time binding is avoided; and a blood product and coarse powder are avoided, and the dressing is all-natural, non-toxic, degradable and high in bio-safety.

The invention relates to application of glaucocalyxin A and particularly relates to application of glaucocalyxin A in preparation of anticoagulation medicaments. The glaucocalyxin A can be used for remarkably prolonging the capillary coagulation time and tail tip bleeding time of mice, and remarkably prolonging the thrombin time (TT), prothrombin time (PT), activated partial thromboplastin time (APTT) and plasma recalcification time (PRT) of the mice. The glaucocalyxin A can be used for remarkably prolonging the TT, APTT and PRT for domestic rabbits in vitro. The results of in-vivo-administration anticoagulation experiments prove that the glaucocalyxin A can be used for remarkably prolonging the APTT and PRT of the mice, thereby prompting that the glaucocalyxin A can be used for inhibiting the generation of fibrin by disturbing intrinsic coagulation factor activity; and the remarkable prolonging of the TT proves the inhibition of transformation from fibrinogen to fibrin. The results of the in-vivo-administration anticoagulation experiments also prove that the glaucocalyxin A has a certain inhibition effect on extrinsic coagulation pathways since the glaucocalyxin A can be used for remarkably prolonging the PT. The results of in-vitro experiments prove that the glaucocalyxin A can be used for remarkably prolonging the APTT, PT and PRT, but has no obvious effects on the PT, thereby proving that the glaucocalyxin A realizes the anticoagulation effect in vitro mainly through inhibiting intrinsic coagulation pathways.

The invention discloses traditional Chinese medicine hemostatic powder and a preparation method thereof. The traditional Chinese medicine hemostatic powder is prepared from, by mass, 10-20 parts of common bletilla pseudobulb, 5-10 parts of sophora japonica, 2-8 parts of typhae pollen, 3-6 parts of agrimonia pilosa ledeb, 2-6 parts of crinis carbonisatus, 8-20 parts of folium artemisiae argyi, 2-5 parts of sanguisorba officinalis, 2-8 parts of trachycarpus fortunei, 3-6 parts of panax notoginseng, 1-3 parts of mint, 10-15 parts of whey protein and 5-10 parts of collagen. The traditional Chinese medicine hemostatic powder is formed by compositing hemostatic traditional Chinese medicine, is used for hemorrhagic wounds, can quickly stop bleeding, greatly shortens bleeding time, and is safe to use and free of side effects.

The invention provides a postoperative pressing hemostasis device for the cardiovascular medicine department. The postoperative pressing hemostasis device comprises a bottom plate, a wrist supporting seat, a pressing assembly and a first electric push rod, wherein a longitudinal supporting column and a base are arranged at the top of the bottom plate; a controller is arranged on the side wall of the base; the wrist supporting seat is arranged at the top of the base, clamping pieces are symmetrically arranged on the wrist supporting seat, and a piece of disinfection gauze is clamped between the two clamping pieces; the pressing assembly is connected with the supporting column through one end of a transverse plate, comprises an arc-shaped pressing plate and is connected with the other end of the transverse plate through a linear pushing device moving in the longitudinal direction; the first electric push rod is arranged in the arc-shaped pressing plate in the longitudinal direction, a push rod head of the first electric push rod is connected with a fixed plate, and a pressure sensing layer is arranged at the bottom of the fixed plate; and the linear pushing device, the controller, the first electric push rod and the pressure sensing layer are all electrically connected with a power supply. The problem in that the bleeding time of a puncture point is shortened by pressing an affected part through cooperative use of the disinfection gauze and the pressing assembly in a short time and reducing blood circulation at the puncture point can be solved.

The invention relates to a pressure swing adsorption (PSA) gas separation device and a control method thereof. In the invention, a middle escape pipe pneumatic valve QV13 is additionally arranged on the basis of the prior art; the connection structure of pipes is as follows: the position of an original pipe pneumatic valve QV-12 is not changed, a four-way pipe of a connecting pipe pneumatic valves QV5, QV6, QV7 and QV8 is changed into a five-way pipe that is respectively connected with the connecting pipe pneumatic valves QV5, QV6, QV7 and QV8 and a connecting pipe pneumatic valves QV13, a three-way pipe of an original connecting pipe pneumatic valves QV3 and QV4 and an evacuation silencer is changed into a four-way pipe that is respectively connected with the other end of the connecting pipe pneumatic valve QV13, the connecting pipe pneumatic valves QV3 and QV4 and the evacuation silencer, and other pipes are not changed; desorption of a regenerated adsorbent is accelerated so as to ensure that the complete desorption of the regenerated adsorbent makes a good foundation for next adsorption and improve the adsorption property of a molecular sieve; and regenerated finished gas for purging is saved, the desorption air bleeding is decreased, the air bleeding time is shortened, the air consumption is decreased, and the user running energy consumption and the production cost can belowered.